Pancreatic Ductal Adenocarcinoma is a Disease of Excessive Autophagy. Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease characterized by early systemic dissemination, perturbation in bioenergetics, inflammation, coagulation, and resistance to chemotherapy. A common link to explain these tumor associated derangements has eluded clinicians and scientists. In genetically engineered murine models of human pancreatic cancer, we have demonstrated that IL-6 mediated autophagy induced by damage associated molecular pattern proteins (DAMPs) is a critical final pro-survival pathway in the tumor microenvironment promoting carcinogenesis, tumor progression and resistance to therapy. Unexpectedly we have now observed excessive autophagic flux is also present within multiple sites/organ systems in both murine models and patients with PDA. We hypothesize that PDA is a systemic disorder of DAMP induced excessive autophagy. Successful treatment will be associated with a return to homeostatic basal autophagy. Here we propose to directly address this hypothesis in patients by performing a randomized clinical trial of preoperative gemcitabine and nab-paclitaxel with or without the autophagy inhibitor hydroxychloroquine. We have recently completed two 'proof of principle'pilot trials of preoperative gemcitabine/hydroxychloroquine and gemcitabine/nab-paclitaxel;demonstrating the feasibility, safety and the potential for improved efficacy with this approach. We will utilize the clinical outcomes and biologic materials from these three clinical trials to investigate the following specific aims:
Specific Aim I : Demonstrate that addition of the autophagy inhibitor hydroxychloroquine improves response to pre-operative gemcitabine and nab-paclitaxel.
Specific Aim 2 : Demonstrate that addition of the autophagy inhibitor hydroxychloroquine will decrease pro-survival pathways in treated tumors.
Specific Aim 3 : Demonstrate that PDA is associated with a state of DAMP induced excessive systemic autophagy.

Public Health Relevance

Adenocarcinoma of the pancreas is expected to be the fourth leading cause of cancer deaths in the United States in 2013. Five year survival is less than 5% and mortality rates are nearly identical to its incidence. We hypothesize that progression and resistance to therapeutic intervention in adenocarcinoma of the pancreas is promoted by HMGB1/RAGE signaling leading to a perpetual state of increased autophagy and resistance to apoptosis. In this proposal we will validate targeting this novel molecular pathway (HMGB1/RAGE) neo- adjuvant clinical trial. The results of this project will provide important preclinical and clinical information that will directly drive future bench-top and bedside studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Timmer, William C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Lotfi, Ramin; Kaltenmeier, Christof; Lotze, Michael T et al. (2016) Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfus Med Hemother 43:120-32
Kang, Rui; Chen, Ruochan; Xie, Min et al. (2016) The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. J Immunol 196:4331-7
Goding, Stephen R; Yu, Shaohong; Bailey, Lisa M et al. (2016) Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells. Clin Immunol :
Diniz, B S; Sibille, E; Ding, Y et al. (2015) Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry 20:594-601
Boone, Brian A; Bahary, Nathan; Zureikat, Amer H et al. (2015) Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol 22:4402-10
Shakir, Murtaza; Tang, Daolin; Zeh, Herbert J et al. (2015) The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow. Pancreas 44:528-34
Huang, Jin; Xie, Yangchun; Sun, Xiaofang et al. (2015) DAMPs, ageing, and cancer: The 'DAMP Hypothesis'. Ageing Res Rev 24:3-16
Sehgal, A R; Konig, H; Johnson, D E et al. (2015) You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia 29:517-25
Chen, Ruochan; Fu, Sha; Fan, Xue-Gong et al. (2015) Nuclear DAMP complex-mediated RAGE-dependent macrophage cell death. Biochem Biophys Res Commun 458:650-5
Ganguli, Mary; Lotze, Michael T (2015) Parkinson Disease and Malignant Disease: Minding Cancer's Own Business. JAMA Oncol 1:641-2

Showing the most recent 10 out of 13 publications